These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22863956)

  • 41. Continuous infusional 5-fluorouracil chemotherapy.
    Olthoff KM; Rosove MH; Shackleton CR; Imagawa DK; Farmer DG; Northcross P; Pakrasi AL; Martin P; Goldstein LI; Shaked A; Busuttil RW
    Ann Surg; 1996 Nov; 224(5):686. PubMed ID: 8916883
    [No Abstract]   [Full Text] [Related]  

  • 42. Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
    Fornaro L; Vivaldi C; Lorenzoni G; Masi G; Bargellini I
    Ann Oncol; 2017 Mar; 28(3):667. PubMed ID: 27993799
    [No Abstract]   [Full Text] [Related]  

  • 43. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
    Fukuda S; Okuda K; Imamura M; Imamura I; Eriguchi N; Aoyagi S
    Surgery; 2002 Mar; 131(3):300-10. PubMed ID: 11894035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chemotherapy].
    Ikeda M; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Okusaka T
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):408-12. PubMed ID: 20332676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
    Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
    Vagefi PA; Hirose R
    J Gastrointest Cancer; 2013 Jun; 44(2):246-7. PubMed ID: 22815137
    [No Abstract]   [Full Text] [Related]  

  • 48. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
    Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
    ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
    Chou JW; Cheng KS; Huang CW
    Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Chan SL; Johnson P
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
    [No Abstract]   [Full Text] [Related]  

  • 51. [Adverse reaction of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Tanaka M; Ando E; Itano S; Sata M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():640-4. PubMed ID: 11762027
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capecitabine in advanced hepatocellular carcinoma.
    Murer F; Pozzan C; Peserico G; Farinati F
    Dig Liver Dis; 2016 Oct; 48(10):1260-1. PubMed ID: 27476466
    [No Abstract]   [Full Text] [Related]  

  • 54. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Sho T; Nakanishi M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Nakai M; Suda G; Ogawa K; Chuma M; Meguro T; Nakamura M; Nagasaka A; Horimoto H; Yamamoto Y; Sakamoto N
    Drugs R D; 2017 Sep; 17(3):381-388. PubMed ID: 28573606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
    Kim EH; Kim BK; Kim DY; Kim SU
    Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):514-5. PubMed ID: 23466449
    [No Abstract]   [Full Text] [Related]  

  • 57. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
    Ponziani FR; Bhoori S; Germini A; Bongini M; Flores M; Sposito C; Facciorusso A; Gasbarrini A; Mazzaferro V
    Liver Int; 2016 Jul; 36(7):1033-42. PubMed ID: 26709844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
    Takeyama H; Beppu T; Higashi T; Kaida T; Arima K; Taki K; Imai K; Nitta H; Hayashi H; Nakagawa S; Okabe H; Hashimoto D; Chikamoto A; Ishiko T; Tanaka M; Sasaki Y; Baba H
    Surg Today; 2018 Apr; 48(4):431-438. PubMed ID: 29110089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
    Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
    Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M; Macaluso FS; Valenza F; Virdone R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.